Ranking · Unmet Need
Trial Gap Index
Burden percentile minus active-trial percentile within the same scope. Positive values flag cancers with high mortality burden but comparatively few active trials. A quantitative signal, not an accusation (CLAUDE.md §324). Caveat (Phase 1): trial counts aggregate a cancer and its NCIt descendants only; registrations phrased at a broader level (e.g. "colorectal cancer" for colon and rectal cancer) are attributed to the broader entity, which can overstate the gap of narrower top-level sites.
Computedci-trial-gap-v1unit: percentile pointshigher = worseAll metrics
| Rank | Δ | Cancer | Trial Gap Index (percentile points) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Colon Neoplasm | +50 | 100 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608867 |
| 2 | ▲2 | Malignant Bladder Neoplasm | +23.3 | 96.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608868 |
| 3 | = | Cutaneous Melanoma | +20 | 93.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608869 |
| 4 | ▲2 | Malignant Laryngeal Neoplasm | +16.7 | 90 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608871 |
| 4 | ▲3 | Malignant Pancreatic Neoplasm | +16.7 | 90 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608870 |
| 6 | ▲2 | Malignant Rectal Neoplasm | +10 | 83.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608873 |
| 6 | ▲3 | Malignant Vulvar Neoplasm | +10 | 83.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608872 |
| 8 | ▲3 | Malignant Kidney Neoplasm | +6.6 | 76.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608874 |
| 9 | ▲3 | Malignant Esophageal Neoplasm | +3.4 | 73.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608875 |
| 10 | ▲4 | Malignant Anal Neoplasm | +3.4 | 70 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608876 |
| 11 | ▲3 | Malignant Salivary Gland Neoplasm | +3.3 | 66.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608877 |
| 12 | ▲1 | Malignant Vaginal Neoplasm | +3.3 | 63.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608878 |
| 13 | ▲11 | Malignant Hypopharyngeal Neoplasm | 0 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608883 |
| 13 | ▲1 | Malignant Liver Neoplasm | 0 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608881 |
| 13 | ▲1 | Malignant Lung Neoplasm | 0 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608880 |
| 13 | ▲7 | Malignant Mesothelioma | 0 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608879 |
| 13 | ▲1 | Malignant Prostate Neoplasm | 0 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608884 |
| 13 | ▲9 | Malignant Testicular Neoplasm | 0 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608885 |
| 13 | ▲17 | Malignant Thyroid Gland Neoplasm | 0 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608882 |
| 20 | = | Malignant Breast Neoplasm | -3.4 | 36.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608886 |
| 20 | ▲5 | Malignant Central Nervous System Neoplasm | -3.4 | 36.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608887 |
| 22 | ▲4 | Malignant Penile Neoplasm | -6.7 | 30 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608888 |
| 23 | ▲3 | Leukemia | -10 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608889 |
| 23 | ▲5 | Malignant Uterine Corpus Neoplasm | -10 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608890 |
| 25 | ▲4 | Malignant Ovarian Neoplasm | -13.3 | 20 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608891 |
| 26 | ▲5 | Non-Hodgkin Lymphoma | -16.6 | 16.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608892 |
| 27 | ▲5 | Malignant Gastric Neoplasm | -16.7 | 13.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608893 |
| 28 | ▲6 | Malignant Cervical Neoplasm | -20 | 10 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608895 |
| 28 | ▲5 | Multiple Myeloma | -20 | 10 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608894 |
| 30 | ▲5 | Hodgkin Lymphoma | -20 | 3.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608896 |
| 31 | ▲5 | Malignant Nasopharyngeal Neoplasm | -30 | 0 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2608897 |
Data updated 16 hours agoSource updated unknown31 eligible entities · inputs hash 42c083a5afae5a6aa2195f16